These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 19390304)

  • 1. KRAS mutations and susceptibility to cetuximab and panitumumab in colorectal cancer.
    Jimeno A; Messersmith WA; Hirsch FR; Franklin WA; Eckhardt SG
    Cancer J; 2009; 15(2):110-3. PubMed ID: 19390304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection.
    Jimeno A; Messersmith WA; Hirsch FR; Franklin WA; Eckhardt SG
    J Clin Oncol; 2009 Mar; 27(7):1130-6. PubMed ID: 19124802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
    J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?
    Rizzo S; Bronte G; Fanale D; Corsini L; Silvestris N; Santini D; Gulotta G; Bazan V; Gebbia N; Fulfaro F; Russo A
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S56-61. PubMed ID: 21129611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
    Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
    Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.
    Bardelli A; Siena S
    J Clin Oncol; 2010 Mar; 28(7):1254-61. PubMed ID: 20100961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. To give or not to give anti-epidermal growth factor receptor (EGFR) monoclonal antibodies to patients with KRAS G13D mutation in advanced colorectal cancer.
    Kim R; Kubal T
    Clin Colorectal Cancer; 2012 Jun; 11(2):85-7. PubMed ID: 22169039
    [No Abstract]   [Full Text] [Related]  

  • 8. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.
    Laurent-Puig P; Cayre A; Manceau G; Buc E; Bachet JB; Lecomte T; Rougier P; Lievre A; Landi B; Boige V; Ducreux M; Ychou M; Bibeau F; Bouché O; Reid J; Stone S; Penault-Llorca F
    J Clin Oncol; 2009 Dec; 27(35):5924-30. PubMed ID: 19884556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meta-analysis of the predictive value of KRAS mutations in treatment response using cetuximab in colorectal cancer.
    Tsoukalas N; Tzovaras AA; Tolia M; Kostakis ID; Papakostidi A; Pistamaltzian N; Ardavanis A
    J BUON; 2012; 17(1):73-8. PubMed ID: 22517696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KRAS mutational status as a predictor of epidermal growth factor receptor inhibitor efficacy in colorectal cancer.
    Baynes RD; Gansert J
    Am J Ther; 2009; 16(6):554-61. PubMed ID: 19352138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer.
    Hecht JR; Douillard JY; Schwartzberg L; Grothey A; Kopetz S; Rong A; Oliner KS; Sidhu R
    Cancer Treat Rev; 2015 Sep; 41(8):653-9. PubMed ID: 26220150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should KRAS mutations be considered an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab?
    Garassino MC; Farina G; Rossi A; Martelli O; Torri V
    J Clin Oncol; 2008 May; 26(15):2600; author reply 2601-2. PubMed ID: 18487581
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical relevance of KRAS mutations in codon 13: Where are we?
    Er TK; Chen CC; Bujanda L; Herreros-Villanueva M
    Cancer Lett; 2014 Feb; 343(1):1-5. PubMed ID: 24051306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of benefit in colorectal cancer treated with cetuximab: are we getting "Lost in TranslationAL"?
    Cremolini C; Loupakis F; Ruzzo A; Perrone G; Rulli E; Vincenzi B; Tonini G; Graziano F; Muda AO; Falcone A
    J Clin Oncol; 2010 Apr; 28(11):e173-4; author reply e175-6. PubMed ID: 20177018
    [No Abstract]   [Full Text] [Related]  

  • 15. KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature.
    de Reyniès A; Boige V; Milano G; Faivre J; Laurent-Puig P
    J Clin Oncol; 2008 May; 26(13):2228-30; author reply 2230-1. PubMed ID: 18445856
    [No Abstract]   [Full Text] [Related]  

  • 16. [Mutation of EGFR signaling pathway and therapy for metastatic colorectal cancer].
    Nozawa K; Watanabe T
    Gan To Kagaku Ryoho; 2010 May; 37(5):791-4. PubMed ID: 20495308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Predictive factors of response to anti-EGFR treatments in colorectal cancer].
    Lièvre A; Laurent-Puig P
    Bull Cancer; 2008 Jan; 95(1):133-40. PubMed ID: 18230579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR.
    Heinemann V; Stintzing S; Kirchner T; Boeck S; Jung A
    Cancer Treat Rev; 2009 May; 35(3):262-71. PubMed ID: 19117687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
    Tol J; Punt CJ
    Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRAS mutation in metastatic colorectal cancer and its impact on the use of EGFR inhibitors.
    Lenz HJ; Chu E; Grothey A
    Clin Adv Hematol Oncol; 2008 Dec; 6(12):1-13, 14-6. PubMed ID: 19378369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.